Skip to main content
Journal cover image

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.

Publication ,  Journal Article
Bossuyt, V; Provenzano, E; Symmans, WF; Boughey, JC; Coles, C; Curigliano, G; Dixon, JM; Esserman, LJ; Fastner, G; Kuehn, T; Peintinger, F ...
Published in: Ann Oncol
July 2015

Neoadjuvant systemic therapy (NAST) provides the unique opportunity to assess response to treatment after months rather than years of follow-up. However, significant variability exists in methods of pathologic assessment of response to NAST, and thus its interpretation for subsequent clinical decisions. Our international multidisciplinary working group was convened by the Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration and tasked to recommend practical methods for standardized evaluation of the post-NAST surgical breast cancer specimen for clinical trials that promote accurate and reliable designation of pathologic complete response (pCR) and meaningful characterization of residual disease. Recommendations include multidisciplinary communication; clinical marking of the tumor site (clips); and radiologic, photographic, or pictorial imaging of the sliced specimen, to map the tissue sections and reconcile macroscopic and microscopic findings. The information required to define pCR (ypT0/is ypN0 or ypT0 yp N0), residual ypT and ypN stage using the current AJCC/UICC system, and the Residual Cancer Burden system were recommended for quantification of residual disease in clinical trials.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

July 2015

Volume

26

Issue

7

Start / End Page

1280 / 1291

Location

England

Related Subject Headings

  • Prognosis
  • Practice Guidelines as Topic
  • Oncology & Carcinogenesis
  • Neoplasm, Residual
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Humans
  • Female
  • Clinical Trials as Topic
  • Chemotherapy, Adjuvant
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bossuyt, V., Provenzano, E., Symmans, W. F., Boughey, J. C., Coles, C., Curigliano, G., … Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration, . (2015). Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol, 26(7), 1280–1291. https://doi.org/10.1093/annonc/mdv161
Bossuyt, V., E. Provenzano, W. F. Symmans, J. C. Boughey, C. Coles, G. Curigliano, J. M. Dixon, et al. “Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.Ann Oncol 26, no. 7 (July 2015): 1280–91. https://doi.org/10.1093/annonc/mdv161.
Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015 Jul;26(7):1280–91.
Bossuyt, V., et al. “Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.Ann Oncol, vol. 26, no. 7, July 2015, pp. 1280–91. Pubmed, doi:10.1093/annonc/mdv161.
Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D, Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015 Jul;26(7):1280–1291.
Journal cover image

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

July 2015

Volume

26

Issue

7

Start / End Page

1280 / 1291

Location

England

Related Subject Headings

  • Prognosis
  • Practice Guidelines as Topic
  • Oncology & Carcinogenesis
  • Neoplasm, Residual
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Humans
  • Female
  • Clinical Trials as Topic
  • Chemotherapy, Adjuvant